Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Ratios

Agios Pharmaceuticals (AGIO) Divestments (2020 - 2021)

Agios Pharmaceuticals (AGIO) has disclosed Divestments for 2 consecutive years, with $1.8 billion as the latest value for Q1 2021.

For Q1 2021, Divestments rose 695080.69% year-over-year to $1.8 billion; the TTM value through Mar 2022 reached -$455000.0, down 100.03%, while the annual FY2024 figure was $200.0 million, N/A changed from the prior year.
Divestments hit $1.8 billion in Q1 2021 for Agios Pharmaceuticals, up from -$455000.0 in the prior quarter.
Across five years, Divestments topped out at $1.8 billion in Q1 2021 and bottomed at -$455000.0 in Q4 2020.